Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 36
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
Pharmaceutical / Industry
CAM307
NCT00046683
Last Modified:
12/14/2007
 
First Published:
5/23/2003
2.
Phase I/II Study of Alemtuzumab During Post-Remission Intensification Therapy in Patients With Untreated Acute Lymphoblastic Leukemia (Phase I portion closed to accrual as of 7/5/2005)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
15 and over
NCI
CALGB-10102
CALGB-10102, NCT00061945
3.
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
0 to 70
Other
H8714
DIMSUM, NCT00048412
Last Modified:
12/12/2007
 
First Published:
5/28/2004
4.
Phase I/II Pilot Study of a Reduced-Intensity Conditioning Regimen Comprising Alemtuzumab, Fludarabine, and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total Body Radiotherapy Followed By Haplotype-Mismatched, KIR Class I Epitope-Mismatched CD34-Positive Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, Refractory, or Poor-Risk Hematological Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 to 60
NCI
CALGB-100102
CALGB-100102, NCT00085449
Last Modified:
2/22/2008
 
First Published:
1/20/2006
5.
Phase I/II Pilot Study of Induction Therapy Comprising Fludarabine and Cyclophosphamide Followed By Allogeneic Stem Cell Transplantation in Patients With High-Risk B-Cell Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 to 65
Other, Pharmaceutical / Industry
GCLLSG-CLL3X
EU-20554, MEDAC-FLUD.10/CLL, NCT00281983
Last Modified:
5/22/2007
 
First Published:
12/1/1999
6.
Phase II Study of Allogeneic Mixed Chimerism Peripheral Blood Stem Cell Transplantation Utilizing In Vivo and In Vitro Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) in Patients With High-Risk Hematologic Malignancies or Refractory Breast or Renal Cell Cancer or Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
DUMC-1340-99-7
NCI-G99-1617, NCT00004143
Last Modified:
12/5/2007
 
First Published:
3/1/2000
7.
Phase II Study of Fludarabine Induction Followed By Alemtuzumab Consolidation in Previously Untreated Patients With Stage I, II, III, or IV B-Cell Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
CLB-19901
NCT00004857, CALGB-19901
Last Modified:
3/30/2005
 
First Published:
10/1/2000
8.
Phase II Study of Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) and Peripheral Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 to 65
NCI
ECOG-8998
E8998, NCT00006390
Last Modified:
8/1/2007
 
First Published:
12/1/2001
9.
Phase II Study of a Nonmyeloablative Regimen Comprising Melphalan, Fludarabine, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Lymphohematopoietic Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
70 and under
NCI
MSKCC-01092
NCI-G01-2028, NCT00027560
Last Modified:
5/8/2008
 
First Published:
3/24/2003
10.
Phase II Study of Alemtuzumab in Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
NU-99H8
NU-99H08, MILLENNIUM-NU-99H8, ILEX-NU-99H8, NCT00057967
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute